Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targetable Molecular Alterations in the Treatment of Biliary Tract Cancers: An Overview of the Available Treatments
Marine Valéry, Damien Vasseur, Francesco Fachinetti, et al.
Cancers (2023) Vol. 15, Iss. 18, pp. 4446-4446
Open Access | Times Cited: 24

Showing 24 citing articles:

FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
Masuko Katoh, Yohann Loriot, Giovanni Brandi, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 4, pp. 312-329
Closed Access | Times Cited: 56
Understanding and Overcoming Resistance to Selective FGFR inhibitors Across FGFR2-Driven Malignancies
Francesco Facchinetti, Yohann Loriot, Floriane Brayé, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 21, pp. 4943-4956
Open Access | Times Cited: 6
Immunotherapy and targeted therapy for cholangiocarcinoma: Artificial intelligence research in imaging
Jiong Liu, Jian Shu
Critical Reviews in Oncology/Hematology (2024) Vol. 194, pp. 104235-104235
Closed Access | Times Cited: 5
The molecular mechanism of gemcitabine in inhibiting the HIF-1α/VEGFB/FGF2/FGFR1 signaling pathway for ovarian cancer treatment
Liangliang Wang, Shanshan Ma, H. Su, et al.
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access
Prognostic Significance of Lymph Node Ratio in Intrahepatic and Extrahepatic Cholangiocarcinomas
Andrii Khomiak, Sumaya Abdul Ghaffar, Salvador Rodriguez Franco, et al.
Cancers (2025) Vol. 17, Iss. 2, pp. 220-220
Open Access
Neoplastic premalignant pancreatobiliary lesions: current update on the spectrum of lesions and their imaging appearances
Anil K. Dasyam, Nikhil V Tirukkovalur, Amir A. Borhani, et al.
Abdominal Radiology (2025)
Closed Access
HER2 Pathway in Biliary Tract Cancer: A Snapshot of the Current Understanding and Future Directions
Silvia Camera, Federico Rossari, Silvia Foti, et al.
Targeted Oncology (2025)
Closed Access
Cost in the United States of FDA-approved small molecule protein kinase inhibitors used in the treatment of neoplastic and non-neoplastic diseases
Robert Roskoski
Pharmacological Research (2023) Vol. 199, pp. 107036-107036
Open Access | Times Cited: 8
Current and Future Therapeutic Targets for Directed Molecular Therapies in Cholangiocarcinoma
Philipp Heumann, Andreas Albert, Karsten Gülow, et al.
Cancers (2024) Vol. 16, Iss. 9, pp. 1690-1690
Open Access | Times Cited: 1
Integrating Molecular Insights into Biliary Tract Cancer Management: A Review of Personalized Therapeutic Strategies
Mar Ros-Buxó, Ezequiel Mauro, Tamara Saurí, et al.
Current Oncology (2024) Vol. 31, Iss. 7, pp. 3615-3629
Open Access | Times Cited: 1
Immunotherapy
Layal Al Mahmasani, James J. Harding, Ghassan K. Abou‐Alfa
Hematology/Oncology Clinics of North America (2024) Vol. 38, Iss. 3, pp. 643-657
Closed Access
Insights into Psychoactive Drug Effects: The Role of Drug Discrimination Techniques
Yan Qiu
Qeios (2024)
Open Access
The Role of Ferroptosis in Inflammatory Bowel Disease: Mechanisms and Therapeutic Implications
Qiu Yan
Qeios (2024)
Open Access
Assessment and Improvement of Nutritional Knowledge among Hospitalized Cancer Patients: Gaps, Sources, and Educational Strategies
Qiu Yan
Qeios (2024)
Open Access
Strategies for Management and Long-term Surveillance of Pediatric Differentiated Thyroid Cancer: Balancing Efficacy and Quality of Life
Dahuang Tao
Qeios (2024)
Open Access
Challenges and Opportunities in Mobile Health Technologies for Cancer Pain Management: An Integrative Review
Dahuang Tao
Qeios (2024)
Open Access
Cholangiocarcinoma Insights: Established Foundations and Cutting-Edge Innovations from Dr. James Cleary’s Pioneering Research
Viviana Cortiana, Harshal Chorya, Muskan Joshi, et al.
Cancers (2024) Vol. 16, Iss. 3, pp. 632-632
Open Access
Advancements in the Detection and Treatment of Rare ALK Fusion Mutations in Hepatocellular Carcinoma: A Case Report and Literature Review
Yan Qiu
Qeios (2024)
Open Access
Efficacy and safety of anlotinib plus anti-PD-1 agents in patients with refractory advanced biliary tract cancers
Tianqi An, Hui Qiu, Hong Zong, et al.
Clinical & Translational Oncology (2024) Vol. 26, Iss. 8, pp. 2006-2019
Closed Access
Futibatinib: A Review in Locally Advanced and Metastatic Cholangiocarcinoma
Sheridan M. Hoy
Targeted Oncology (2024) Vol. 19, Iss. 3, pp. 473-480
Closed Access
Molecularly targeted therapy for biliary cancer
I. V. Savchenko, I. А. Dzhanyan, Е. Yu. Antonova, et al.
P A Herzen Journal of Oncology (2024) Vol. 13, Iss. 3, pp. 34-34
Closed Access
Molecular Differences With Therapeutic Implications in Early-Onset Compared With Average-Onset Biliary Tract Cancers
Thejus Jayakrishnan, Yasmine Baca, Joanne Xiu, et al.
JCO Precision Oncology (2024), Iss. 8
Closed Access
Antibody-Drug Conjugates and Their Potential in the Treatment of Patients with Biliary Tract Cancer
Shaun Alexander, Umair Aleem, Timothy W. Jacobs, et al.
Cancers (2024) Vol. 16, Iss. 19, pp. 3345-3345
Open Access
Superior survival benefits of triple combination immunotherapy compared to standard chemotherapy as second-line treatment for advanced biliary tract cancer: a retrospective analysis
Peipei Shang, Heming Xu, Tianmei Zeng, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access
Page 1

Scroll to top